Corporate Presentation September 4, 2026 Climb Bio Investor Presentation September 2026 R&D Spotlight Series September 3, 2026 CLYM116 Initial Phase 1 Results May 5, 2026 Budoprutug and the CD19 Opportunity September 29, 2025 CLYM116 and the IgA Nephropathy (IgAN) Opportunity
